Retatrutide Reconstitution Calculator

Classification: Investigational synthetic peptide with activity at the GIP, GLP-1, and glucagon receptors.

Overview

Retatrutide is a synthetic peptide being studied as a single molecule with activity at three hormone-receptor systems: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. Its development code is LY3437943. Calling it a “triple agonist” describes the pharmacology investigated in research; it does not establish an approved use or predict an individual result.

This page is an arithmetic utility for label values supplied by the visitor. It can relate a mass amount, the liquid volume entered by the visitor, the resulting concentration, and a syringe display scale. It does not identify a product, validate a source, determine whether a container is authentic, or decide an amount. A professional or official product information should be consulted for questions outside arithmetic.

Concentration is a relationship between mass and liquid volume. If the visitor enters a different volume, the calculated mass-per-volume relationship changes even though the mass entered for the container has not changed. Syringe units describe a liquid scale, not retatrutide mass. The same displayed units can therefore correspond to different masses when concentration or syringe scale differs.

Research context

A peer-reviewed phase 2 obesity trial described retatrutide as acting at GIP, GLP-1, and glucagon receptors and evaluated clinical outcomes under a controlled research design. A separate phase 2 diabetes study examined the same investigational molecule in adults with type 2 diabetes. These studies show that retatrutide has been investigated in humans; they do not turn a visitor-entered vial into an approved medicine.

The ClinicalTrials.gov record for the cardiovascular and kidney outcomes program documents continuing clinical development. A 2026 peer-reviewed phase 3 report is also indexed in PubMed. Research stage, trial findings, and regulatory authorization are separate questions, so PepLedger presents them separately rather than translating trial findings into personal guidance.

Evidence and regulatory status

The FDA page linked below says retatrutide is not a component of an FDA-approved drug and addresses its unapproved status and compounding restrictions. The ClinicalTrials.gov records and PubMed articles establish research activity, not authorization. At the stated review date, no FDA-approved retatrutide indication is asserted by this page.

Evidence is limited by the designs, populations, follow-up periods, comparators, and publication status of individual studies. A trial result cannot establish suitability for a particular person, product quality, or the identity of material represented by an unlabeled or independently sourced container.

Unit notes

Mass fields accept mg or mcg. The universal conversion is 1 mg = 1,000 mcg. Liquid volume is entered in mL. Concentration must be known before a liquid volume can be related to a mass amount.

U-100 means 100 units per mL, and U-40 means 40 units per mL. Units are scale markings, not a mass unit. A custom scale must be interpreted from its entered units-per-mL value. Shortcuts are data-entry conveniences only, not selected settings or instructions.

Limitations

  • The calculator performs unit conversion and concentration arithmetic only. It cannot assess sterility, purity, stability, compatibility, authenticity, eligibility, adverse effects, interactions, or regulatory compliance. It does not provide preparation, handling, administration, or product-acquisition instructions.
  • Use the exact units printed on the relevant label. If a value is missing, ambiguous, or inconsistent, the arithmetic output cannot resolve that uncertainty. Results describe only the values entered and should not be read as a clinical conclusion.

Frequently asked questions

What does the Retatrutide calculator calculate?

It uses the visitor’s vial mass, liquid volume, amount to calculate, and selected syringe scale to calculate concentration, liquid volume, and displayed units. It does not select an amount.

Is retatrutide FDA approved?

The FDA source listed on this page describes retatrutide as unapproved and says it is not a component of an FDA-approved drug as of the review date. Research participation and regulatory authorization are not the same thing.

What are LY3437943 and retatrutide?

LY3437943 is the development identifier for retatrutide. The record uses “triple hormone-receptor agonist” as a pharmacology description, not as a second product identity.

Why can the same syringe units represent different masses?

Syringe units describe a liquid scale. Mass depends on concentration, and concentration depends on the entered mass and liquid volume, so identical scale readings need not represent identical masses.

Does PepLedger determine an amount for retatrutide?

No. PepLedger performs arithmetic using values entered by the visitor and does not determine or recommend an amount.

What if the label does not identify the liquid volume?

The calculator cannot infer a missing value. Enter only a verified value; otherwise the result cannot establish the concentration represented by that container.

Sources and official references

Calculation methodology

PepLedger calculates concentration, liquid volume and syringe-scale position exclusively from the values you enter. It does not choose or recommend an amount.

View our calculation methodology and editorial standards

Last updated: September 13, 2026

Related tools